新闻BenzingaReported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events Benzinga 2026.11.16 05:33 (GMT+0) 在Benzinga上打开 其他新闻 意大利机器人初创公司Mosaico完成750万欧元种子轮融资 某钱包一天内买入145,580枚LINK,约合134万美元 分析:财库抛售叠加ETF流出与高OI,BTC十天跌至6.2万美元 火币HTX首席分析师Cloud:本轮下跌中需求端并未崩塌,筹码正从ETF转向企业资产负债表 某巨鲸过去16天里卖出14亿枚PUMP并买入HYPE SOL现货 ETF 上周净流出 3205.38 万美元,创历史第二高